ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

On location

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of the BCL2 protein, combining the BCL2 inhibitor venetoclax with...
On location

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response rates and prolonged time to next treatment, compared with...
On location

Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma

Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome inhibitor (PI) ixazomib in patients with newly diagnosed multiple...

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after I returned from my first American Society of Hematology...

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with advanced myelodysplastic syndromes (MDS), compared with OS in patients...

Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab responded to treatment with melflufen, according to interim data...

Mixed Results for Immunotherapy Approaches in Myelodysplastic Syndromes

Findings from trials evaluating new treatment strategies for patients with myelodysplastic syndromes (MDS) produced mixed results: Combining an immune checkpoint inhibitor with azacitidine was...

Predicting Response to Alvocidib in Patients With Relapsed/Refractory AML

The CDK9 inhibitor alvocidib induced a high rate of responses in patients with relapsed or refractory acute myeloid leukemia (AML) who had MCL1-dependent disease,...

Age, Blood Type, and Rituximab Use Associated With Relapse Risk in TTP

For patients with thrombotic thrombocytopenic purpura (TTP), treatment with rituximab prevented relapse in the first year after administration, but the protective effect waned over...

Evaluating Imetelstat for Patients With Relapsed/Refractory Myelofibrosis

In a phase II trial presented at the 2018 ASH Annual Meeting conducted in patients with higher-risk myelofibrosis (MF) who had relapsed following or...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.